Pancreatic cancer: What is new in 2005?;Cancer du pancréas: Quoi de neuf en 2005?

Bulletin du Cancer

Volumn 93, Issue 1, 2006, Pages 67-72

  Hammel, Pascal ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Adjuvant treatment; Chemotherapy; Pancreatic cancer; Radiotherapy; Surgery

Indexed keywords

CAPECITABINE; ERLOTINIB; GEMCITABINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SUSCEPTIBILITY; ENVIRONMENTAL FACTOR; FEEDING BEHAVIOR; HEREDITY; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACOGENOMICS; PREOPERATIVE EVALUATION; PROTEOMICS; REVIEW; TOBACCO DEPENDENCE; TREATMENT PLANNING;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; RISK ASSESSMENT;

EID: 33144480294     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol GI 2005; 2: A77.
2. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, et al. Phase III randomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreatic cancer. ECCO, 2005; APS11.
3. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a Gercor and Giscad phase III trial. J Clin Oncol 2005; 23: 3509-16.
4. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-40.
5. Bruckner HW, Hrehorovich VR, Sawhney HS. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res 2005; 25: 3637-9.
6. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-5.
7. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). ASCO, 2005; A4010.
8. Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23: 1228-36.
9. El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, et al. A phase II study of celecoxib, gemcitabine and cisplatine in advanced pancreatic cancer. Invest New Drugs 2005, Jul 18 (on line).
10. Huguet F, André T, Hammel P, Artru P, Balosso P, Ruszniewski P, et al. Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: retrospective analysis of 181 patients enrolled in prospective phases II and III Gercor studies. ASCO, 2005; A4095.
11. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 2005; 28: 345-50.
12. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005; 62: 1345-50.
13. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.
14. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. ASCO, 2005; A4013.
15. Delpero JR. Chirurgie: indications et avancées récentes. In: Lledo G, ed. Le cancer du pancréas exocrine. Paris: John Libbey Eurotext, 2004: 69-94.
16. Schwartz RE, Smith DD. Extent of lymph node staging for pancreatic cancer: information from a large U.S. database. ASCO GI, 2005; A82.
17. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Belleannee G, et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005; 201: 359-65.
18. Turrini O, Moutardier V, Guiramand J, Lelong B, Bories E, Sannini A, et al. Haemorrhage after duodenopancreatectomy: impact of neoadjuvant radiochemotherapy and experience with sentinel bleeding. World J Surg 2005; 29: 212-6.
19. Müller-Nordhorn J, Bruggenjurgen B, Bohmig M, Selim D, Reich A, Noesselt L, et al. Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther 2005; 22: 405-15.
20. Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, et al. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn J Clin Oncol 2005; 35: 526-30.
21. Kwekkeeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTAO, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-62.
22. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-71.
23. Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-9.
24. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-72.
25. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005; 24: 6626-36.
26. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-21.
27. Matsubayashi H, Skinner HG, Jacobuzio-Donahue C, Abe T, Sato N, Riall TS, et al. Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. Clin Gastroenterol Hepatol 2005; 3: 752-60.
28. Wang L, Miao X, Tan W, Lu X, Zhao P, Zhao X, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005; 3: 743-51.
29. Brand RE, Gorchow A, Brand RM. The effect of smoking on the age of pancreatic adenocarcinoma diagnosis. ASCO GI, 2005; A76.
30. Nothlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Kolonel LN. Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 2005; 97: 1458-65.